Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.
Breast cancer
Guideline implementation
Hypofractionation
Radiotherapy
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
26
09
2020
accepted:
30
11
2020
pubmed:
16
12
2020
medline:
1
4
2022
entrez:
15
12
2020
Statut:
ppublish
Résumé
Hypofractionated radiotherapy is the standard of care for adjuvant whole breast radiotherapy (RT). However, adoption has been slow. The indication for regional nodal irradiation has been expanded to include patients with 0-3 involved lymph nodes. We investigated the impact of the publication of the updated German S3 guidelines in 2017 on adoption of hypofractionation and enrollment of patients with lymph node involvement within a randomized controlled phase III trial. In the experimental arm of the HYPOSIB trial (NCT02474641), hypofractionated RT with simultaneous integrated boost (SIB) was used. In the standard arm, RT could be given as hypofractionated RT with sequential boost (HF Enrollment of patients with involved lymph nodes was low throughout the trial. Adoption of HF The use of HF
Identifiants
pubmed: 33320286
doi: 10.1007/s00066-020-01730-9
pii: 10.1007/s00066-020-01730-9
pmc: PMC8397631
doi:
Banques de données
ClinicalTrials.gov
['NCT02474641']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
802-811Subventions
Organisme : Deutsche Krebshilfe
ID : 110897
Informations de copyright
© 2020. The Author(s).
Références
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Strahlenther Onkol. 2020 Jan;196(1):15-22
pubmed: 31722060
Lancet Oncol. 2006 Jun;7(6):467-71
pubmed: 16750496
Strahlenther Onkol. 2014 Jul;190(7):646-53
pubmed: 24737540
Strahlenther Onkol. 2019 Jan;195(1):13-20
pubmed: 30143814
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):683-693
pubmed: 32437921
Breast Care (Basel). 2019 Aug;14(4):224-245
pubmed: 31558897
J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50
pubmed: 12165639
Breast Cancer Res Treat. 2017 Sep;165(2):445-453
pubmed: 28639030
Radiat Oncol. 2020 Oct 13;15(1):235
pubmed: 33050920
Breast. 2015 Oct;24(5):656-60
pubmed: 26371691
Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):775-779
pubmed: 32904392
Radiother Oncol. 2013 Aug;108(2):269-72
pubmed: 24055289
Radiat Oncol. 2016 Feb 02;11:16
pubmed: 26830843
Cochrane Database Syst Rev. 2016 Jul 18;7:CD003860
pubmed: 27425588
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1056-1088
pubmed: 30581198
J Clin Oncol. 2016 Feb 1;34(4):314-20
pubmed: 26598752
Breast Cancer Res Treat. 2017 Apr;162(2):317-328
pubmed: 28120272
JAMA. 2014 Dec 17;312(23):2542-50
pubmed: 25494006
Radiother Oncol. 2014 Jan;110(1):39-44
pubmed: 24440047
Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e471-7
pubmed: 22494592
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
J Med Imaging Radiat Oncol. 2019 Aug;63(4):530-537
pubmed: 31087640
Radiat Oncol. 2015 Jul 09;10:139
pubmed: 26156086
Breast Care (Basel). 2019 Aug;14(4):247-255
pubmed: 31558898
Strahlenther Onkol. 2020 Sep;196(9):771-778
pubmed: 32488292
Strahlenther Onkol. 2021 Jan;197(1):48-55
pubmed: 33001241
Radiother Oncol. 2021 Feb;155:17-26
pubmed: 33065187
N Engl J Med. 2015 Jul 23;373(4):307-16
pubmed: 26200977
N Engl J Med. 2015 Jul 23;373(4):317-27
pubmed: 26200978
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Sci Rep. 2019 Feb 26;9(1):2759
pubmed: 30808911